Timothy D. Moore

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer et al. · Journal of Clinical Oncology · 2019 · 406 citations · Full text

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Thomas E. Witzig, Peter H. Wiernik, Timothy D. Moore et al. · Journal of Clinical Oncology · 2009 · 256 citations · Full text

Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.

Jacqueline Plowman, William R. Waud, Antonis D. Koutsoukos et al. · PubMed · 1994 · 132 citations

Tumor Growth Delay, U251 Model, Pharmacotherapy +16

SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer

G. Thomas Budd, William E. Barlow, Halle C. F. Moore et al. · Journal of Clinical Oncology · 2014 · 119 citations · Full text

RecN protein and transcription factor DksA combine to promote faithful recombinational repair of DNA double‐strand breaks

Tom R. Meddows, Andrew P. Savory, Jane I. Grove et al. · Molecular Microbiology · 2005 · 118 citations · Full text